摘要
目的:总结国内外对乳腺癌原发灶与转移灶激素受体(HR)和HER-2一致性的研究现状,探讨其临床意义。方法:应用PubMed和CNKI期刊全文数据库检索系统,以"乳腺癌、HR和HER-2"等为关键词,检索2005-2010年的相关文献356条。纳入标准:1)HR和HER-2的检测方法;2)乳腺癌原发灶与转移灶HR或HER-2的表达。根据纳入标准,符合分析的文献16篇。结果:国内外学者的相关研究,主要有3种结论:1)HR、HER-2在原发灶与复发转移灶间的表达差异有统计学意义,P<0.05;2)HR、HER-2在原发灶与复发转移灶间的表达有不一致性,但差异无统计学意义,P>0.05;3)PR、HER-2在原发灶与复发转移灶间不存在差异。结论:确定乳腺癌复发/转移灶中HR及HER-2的表达状况,对患者术后是否需要接受内分泌或分子靶向治疗及预后判断有指导作用。
OBJECTIVE： To summarize the research progress on consistence of ER, PR and HER-2 in primary breast cancer and recurrent/metastatic sites, and explore the clinical significance. METHODS： A total of 356 papers were searched with breast cancer, ER and HER-2 as key words in PubMed and CNKI databases from 2005 to 2010. Sixteen papers were selected according to the standards as follows： 1 ）the determination methods of HR and HER-2. 2）the expression of HR and HER 2 in primary breast cancer and recurrent/metastatic sites. RESULTS： There are mainly 3 conclusions： 1）Differences in expression level of HR and HER-2 between primary and recurrent/metastatic sites of breast caner are significant（P〈0.05） ; 2）The expression level of HR and HER-2 between primary and recurrent/metastatic sites of breast caner are inconsistent （P〈0.05） ; 3）The expression level of PR and HER-2 between primary and recurrent/metastatic sites of breast caner are cordanee. CONCLSUION： The expression of HR and HER-2 in re current/metastatic sites has guidance effect for the patients of breast cancer whether they accept hormone and target therapy and prognosis after the operation.
出处
《中华肿瘤防治杂志》
CAS
2011年第9期734-736,共3页
Chinese Journal of Cancer Prevention and Treatment
